Retina International World Congress 2024 Speaker Spotlight: Dr. Bart Leroy

Our Retina International World Congress (RIWC24) takes place from the 5th – 8th June 2024 in the Dublin Royal Convention Centre, in the heart of Dublin city centre.

Our Scientific Committee has been working relentlessly to secure an impressive lineup of outstanding speakers to shed light on this research area so as part of our Meet the Speaker series, we are delighted to announce one more distinguished speaker.

Dr. Bart Leroy is a Professor of Ophthalmology, Ophthalmic Genetics & Visual Electrophysiology at Ghent University, Belgium, and the Head of the Ophthalmology department at Ghent University Hospital where he has been working for more than 20 years to date.

Headshot of Dr. Bart Leroy on a blue background image. Text: Retina International World Congress. Dublin Royal Convention Centre, Dublin, Ireland. RIWC24. DUBLIN: Targeting the Cure. JUNE 5-8, 2024. DR. BART LEROY, Professor of Ophthalmology, Ghent University & Head of the Ophthalmology Dept., Ghent University Hospital. At the bottom of the image, there are the Fighting Blindness and Retina International logos.

Dr. Bart Leroy has been working in the Ghent hospital for more than 20 years to date and has significant experience in a variety of Inherited Retinal Degenerations (IRDs), where he is involved in both clinical phenotyping (diagnosis of the patients’ condition) as well the development of treatments.

As a certified ophthalmologist and clinical geneticist, Dr. Leroy has been the clinical investigator on gene therapies for CEP290-IRD as well as RPE65-IRD. He was part of the team led by Professors Jean Bennett, Albert Maguire, and Katherine High that helped bring Luxturna to market, the first US FDA-approved gene therapy.*

We are delighted to have Dr. Bart Leroy with us at the Retina International World Congress to present on IRDs and diagnostic methods on the below dates:

  • Genetic Architecture of Retinal Degenerations & Diagnostic Methods, on our Scientific Day Friday, June 7, 2024 and
  • Genetic Testing Pathway, on our Public and Patient Engagement Day, Saturday, June 8, 2024.

You can learn more about Dr. Leroy in the full bio below.

Stay tuned for more updates and registration details as we draw closer to this incredible gathering of the latest scientific research and innovation, set to take place in 2024.

Dr. Bart Leroy

Dr. Bart Leroy is a Professor of Ophthalmology, Ophthalmic Genetics & Visual Electrophysiology at the Ghent University, Belgium, and the Head of the Ophthalmology department in Ghent University Hospital where he has been working for more than 20 years to date.

Dr. Leroy has significant experience in a variety of Inherited Retinal Degenerations (IRDs), including congenital amaurosis, Stargardt disease, retinitis pigmentosa, and other genetic syndromes and diseases.   He is involved in both clinical phenotyping (diagnosis of the patients’ condition) as well the development of treatments.

As a certified ophthalmologist and clinical geneticist, Dr. Leroy has been the clinical investigator on gene therapies for CEP290-IRD as well as RPE65-IRD. He was part of the team led by Professors Jean Bennett, Albert Maguire, and Katherine High that helped bring Luxturna to market, the first US FDA-approved gene therapy.*

Since August 2013, Bart also has a part-time position as an attending physician at the Department of Ophthalmology and the Center for Cellular & Molecular Therapeutics at The Children’s Hospital of Philadelphia, Philadelphia, PA, USA. In collaboration with the team at the University of Pennsylvania and the Children’s Hospital of Philadelphia, Bart is involved in gene therapy projects for inherited retinal blindness there.

Dr. Leroy’s academic background includes a PhD focused on Ophthalmic Genetics and Innovative Treatments for inherited blindness from Ghent University, and extensive studies both in Belgium and abroad. Before his PhD he completed two fellowships in the fields of inherited retinal diseases, visual electrophysiology, medical retina and molecular genetics at Moorfields Eye Hospital and the Institute of Ophthalmology, University College London, London, UK.

He is a member and Board member of several professional organisations, including the International Society for Genetic Eye Disease & Retinoblastoma, the Société de la Génétique Ophtalmologique Francophone and the Belgian Society of Ophthalmology. Last but not least, Dr. Leroy is also co-opted board member for ophthalmic genetics of the European Society of Retina Specialists (EURETINA) and has served as past president for the European Organization for Vision & Eye Research.

 

*We are delighted to also have Prof. Bennett presenting in our RIWC24 and you can learn more here.